{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-040217","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2023-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.454508+00:00","generated_at":"2026-06-14T23:54:36.193279+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Unicycive Q1 net loss $14.6M ($0.97/sh) vs $3.5M loss YoY; cash $24.3M from $30M upfront financing","bullets":["Net loss of $14.6M ($0.97/sh) compared to $3.5M ($0.24/sh) in Q1 2022; includes $10.4M change in warrant liability.","Licensing revenue $0.7M from Lotus Pharma agreement for Renazorb in South Korea signed February 2023.","Cash and cash equivalents $24.3M (Dec 2022: $0.5M) after $30M upfront from up to $130M private placement.","Plans to file NDA for Renazorb by Q3 2023 with potential approval and launch in 2024.","UNI-494 Phase 1 first cohort enrolled; plans to file IND in 2024 for Phase 2 trial in AKI."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-040217","json":"https://secwatch.observer/filing/0001213900-23-040217.json","markdown":"https://secwatch.observer/filing/0001213900-23-040217.md","text":"https://secwatch.observer/filing/0001213900-23-040217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023040217/0001213900-23-040217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023040217/ea178564-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T23:54:36.193279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91c47f3b093ea16ba2bedff4ed9e1482ab83ef70","claim":"Unicycive Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $0.7 million, net income $14.6 million, EPS $0.97 per share of common stock.","evidence_excerpt":"Renal Association Congress (ERA 2023) taking place in Milan, Italy from June 15-18, 2023. Financial Results for the First Quarter Ended March 31, 2023 Licensing revenues were $0.7 million for the quarter ended March 31, 2023 due to a licensing agreement executed in February 2023. Research and development expenses for the quarter ended March 31, 2023 were $3.0","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023040217/0001213900-23-040217-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$0.7 million"},{"label":"Net income","value":"$14.6 million"},{"label":"EPS","value":"$0.97 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}